Compounded Semaglutide and Tirzepatide in 2026: What FDA's Rules Mean for NPs and Med Spas
Key answers
- FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the shortage-era enforcement discretion for pharmacy compounding has ended.
- As of FDA's April 1, 2026 update, neither drug is on the drug shortage list or the 503B bulks list.
- Under section 503A, compounding a copy of a commercially available drug is limited, and one exception requires a prescriber's documented, patient-specific "significant difference."
- FDA says adding vitamin B12 does not by itself make compounded semaglutide a different product.
- FDA's September 2026 warning letter to Empower Pharmacy questioned significant-difference statements repeated word for word or chosen from pre-set menus.
- FDA has warned firms for marketing compounded GLP-1s as the "same as" approved drugs and for vial branding that hides who compounded them.
Questions this article answers
- Is compounded semaglutide still legal in 2026?
- Does adding B12 make compounded semaglutide a different drug?
- What is a 'significant difference' determination?
- Can a med spa put its own logo on compounded GLP-1 vials?
- Can I call compounded semaglutide 'generic'?
- How long can a patient use a multi-dose compounded GLP-1 vial?
This article is regulatory education for licensed clinicians. It is not dosing guidance.
GLP-1 programs became a common add-on for aesthetic practices during the shortage years, often built on compounded semaglutide or tirzepatide. The rules under those programs have changed, and FDA has spent 2026 enforcing the new ones. If you prescribe, administer or sell a GLP-1 program, here’s what FDA has actually said, with links to each document.
The timeline: from shortage to “commercially available”
Compounding pharmacies had more room to make semaglutide and tirzepatide while the drugs were on FDA’s shortage list. FDA’s compounding policy page records how that ended:
- Tirzepatide. FDA first determined the shortage was resolved on October 2, 2024, and reaffirmed that decision after re-evaluation on December 19, 2024. After a federal court denied a preliminary injunction on March 5, 2025, the enforcement discretion period ended for state-licensed (503A) pharmacies. For outsourcing facilities (503B), it ran until March 19, 2025.
- Semaglutide. FDA determined the shortage was resolved on February 21, 2025. After the court denied a preliminary injunction on April 24, 2025, the period ended for 503A pharmacies. For 503B facilities it ran until May 22, 2025.
FDA’s September 2026 warning letter to Empower Pharmacy states the end dates as March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide (warning letter, footnote 3).
The FDA-approved products remain on the market. Wegovy’s current label, for example, covers semaglutide injection and tablets (DailyMed). When a shortage is resolved, FDA generally considers the drug commercially available again.
What 503A and 503B mean for your supplier
Federal law treats two kinds of compounders differently. From FDA’s compounding Q&A:
- 503A (state-licensed pharmacies and physicians). State boards of pharmacy have primary day-to-day oversight. These compounders aren’t subject to current good manufacturing practice (CGMP) requirements.
- 503B (outsourcing facilities). These register with FDA, are inspected by FDA on a risk-based schedule, and must meet CGMP requirements.
FDA’s April 1, 2026 update adds two points that matter for GLP-1s:
- For 503A, the drug must be compounded for an individual patient based on a prescription. The compounder may not regularly or in inordinate amounts compound drugs that are “essentially copies” of a commercially available product.
- For 503B, outsourcing facilities generally can’t compound from bulk drug substances unless the substance is on the 503B bulks list or the drug is on the shortage list. FDA states: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
“Essentially a copy” and the significant-difference exception
This is the part that touches prescribers directly.
Per FDA’s April 2026 update, the agency intends to treat a compounded drug as essentially a copy when it has the same active ingredient in the same, similar or an easily substitutable strength, and the commercial product can be used by the same route. The exception is when “a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient.”
FDA also said it doesn’t intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.
The B12 question
Many compounded products add vitamin B12 or niacinamide. FDA addressed this directly. It may consider semaglutide plus vitamin B12 (cyanocobalamin) to be essentially a copy when:
- it’s given by the same route as the commercial products (for example, by injection), and
- the amounts of semaglutide and B12 are within 10% of the strengths of the respective commercial products.
In other words, an added ingredient doesn’t on its own make a compounded GLP-1 a different drug in FDA’s eyes.
What the Empower warning letter tells prescribers
On September 18, 2026, FDA sent a warning letter to Empower Pharmacy after a November 2025 inspection. FDA said products including semaglutide/cyanocobalamin and tirzepatide/niacinamide appeared to be essentially copies of FDA-approved products. It said “the volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual.”
The evidence FDA described is what prescribers should study:
- Orders or prescriptions with no prescriber determination of significant difference.
- Significant-difference statements that “appear to be repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber.”
- The volume of particular products compounded.
FDA added that third-party technology platforms that give prescribers “pre-selected menu options for choosing a statement of significant difference” call the individualized nature of those determinations into question.
The letter is addressed to a pharmacy, not to prescribers. But the documentation it criticizes is written by prescribers. If your GLP-1 program runs through a platform that fills in the significant-difference line for you, read this letter closely.
Marketing: what FDA has warned firms about
On March 3, 2026, FDA announced 30 warning letters to telehealth companies over compounded GLP-1 marketing. FDA said the primary violations were:
- claims implying the compounded product is the same as an FDA-approved product, and
- advertising products branded with the firm’s own name or trademark without qualification, which implies the firm is the compounder.
FDA’s release also states that “compounded drugs are also not the same as generic drugs, which are FDA-approved.” For a med spa website or social post, the safe takeaways are plain. Don’t call a compounded product “generic.” Don’t say it’s “the same as” a brand. Don’t show vials branded in a way that hides the pharmacy that made them.
Safety issues FDA and researchers have flagged
FDA’s concerns page lists several issues worth building into your protocols:
- Dosing errors. FDA has received adverse event reports, some requiring hospitalization, tied to patients mis-measuring doses and, in some cases, clinicians miscalculating them. It has also received reports tied to doses beyond the approved label or faster titration.
- Multi-dose vials. FDA generally recommends discarding multi-dose vials of sterile medication within 28 days after first use, even if the compounder’s instructions say longer, and using a new sterile needle and syringe for each dose.
- Salt forms. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs, and that it isn’t aware of any lawful basis for using them in compounding.
- Retatrutide and cagrilintide. FDA says these cannot be used in compounding under federal law. It has also warned sellers of products labeled “for research purposes” or “not for human consumption.”
- Adverse event reports. As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA notes that 503A pharmacies aren’t required to report adverse events, so these are likely underreported, and that causation can’t always be determined.
Peer-reviewed work points the same way:
- A 2023 poison control case series in the Journal of the American Pharmacists Association described three patients with adverse events after incorrect administration of compounded semaglutide. Two self-administered 10-fold dosing errors, and one patient dosed in milliliters and units rather than milligrams (PubMed).
- A pharmacovigilance study in Expert Opinion on Drug Safety found 707 reports involving compounded products among 81,078 GLP-1 receptor agonist reports in FDA’s adverse event database from 2018 to 2024. Compounded products had higher reporting odds for several adverse events and for preparation and prescribing errors. The authors say the study wasn’t designed to show cause and effect (PubMed).
- A 2025 review in the American Journal of Managed Care noted fraudulent compounded semaglutide batches. It encouraged clinicians to direct patients to lawful sources and to counsel on dosing and administration (PubMed).
The approved products carry their own warnings too. Wegovy’s label has a boxed warning about thyroid C-cell tumors seen in rodents (DailyMed).
A compliance checklist for GLP-1 programs
Use this as a starting point with your medical director, pharmacist and attorney:
- Know your supplier’s category. Is it a 503A pharmacy licensed in the patient’s state, or a registered 503B outsourcing facility? What can each lawfully make for you today?
- Write patient-specific determinations yourself. If you document a significant difference, tie it to this patient’s clinical need, in your own words.
- Check the label. The label should name the actual compounder. Your practice’s branding shouldn’t imply that you made the drug.
- Clean up marketing. Remove “generic,” “same as Ozempic/Wegovy,” “FDA-approved compounded” and similar claims from your site, ads and social posts.
- Teach dosing in milligrams. Confirm the patient’s syringe and the units you’re using, and document the counseling.
- Set vial rules. Follow FDA’s 28-day multi-dose vial recommendation and storage guidance, and tell patients not to use product that arrives warm.
- Report problems. Send adverse events and quality issues to FDA’s MedWatch program.
- Check your state. Who may prescribe, administer and dispense GLP-1s, and under what supervision, is set by your state boards, not by FDA.
Where TMAA helps
- GLP-1 course. TMAA’s GLP-1 course has 11 modules, bonuses and 60 days of the AI tutor included.
- S.A.G.E. Ask questions about your state’s GLP-1 rules with a free TMAA account, which includes 3 S.A.G.E. questions a day. S.A.G.E. is not legal advice. For a binding answer, talk to a healthcare attorney in your state.
- S.A.G.E. GLP-1 tutor. The tutor is part of TMAA Pro, $39 every 4 weeks or $390 a year.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Compounding is still lawful when the conditions of federal law are met, but the shortage-era flexibility is over. FDA says semaglutide and tirzepatide are not on its drug shortage list or the 503B bulks list, and copies of approved products face strict limits.
Does adding B12 make compounded semaglutide a different drug?
Not by itself. FDA says it may treat semaglutide plus vitamin B12 as essentially a copy of commercially available products when the route is the same and both strengths are within 10% of commercial products.
What is a 'significant difference' determination?
It is a prescriber's documented determination that a change in the compounded drug produces a significant difference for an identified individual patient. FDA's 2026 Empower warning letter questioned statements repeated verbatim or picked from pre-set menus.
Can a med spa put its own logo on compounded GLP-1 vials?
FDA's March 2026 warning letters cited telehealth firms for advertising compounded products branded with the firm's name without qualification, which implied the firm was the compounder.
Can I call compounded semaglutide 'generic'?
No. FDA says compounded drugs are not the same as generic drugs, which are FDA-approved, and it has warned firms for claims implying sameness with approved products.
How long can a patient use a multi-dose compounded GLP-1 vial?
FDA generally recommends discarding multi-dose vials of sterile medication within 28 days after first use, even if medication remains and even if the compounder's instructions say longer.
Sources
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. Accessed November 16, 2026.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. Accessed November 16, 2026.
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration. Accessed November 16, 2026.
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. U.S. Food and Drug Administration. Accessed November 16, 2026.
- Warning Letter: Empower Clinic Services, LLC dba Empower Pharmacy, MARCS-CMS 738238 (September 18, 2026). U.S. Food and Drug Administration. Accessed November 16, 2026.
- WEGOVY (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine. Accessed November 16, 2026.
- Administration errors of compounded semaglutide reported to a poison control center: case series (J Am Pharm Assoc, 2023). PubMed, U.S. National Library of Medicine. Accessed November 16, 2026.
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using FAERS (Expert Opin Drug Saf, 2026). PubMed, U.S. National Library of Medicine. Accessed November 16, 2026.
- Navigating compounded semaglutide: what health care providers need to know (Am J Manag Care, 2025). PubMed, U.S. National Library of Medicine. Accessed November 16, 2026.